行情

LPCN

LPCN

Lipocine
NASDAQ

实时行情|Nasdaq Last Sale

0.4369
+0.0049
+1.13%
交易中 14:25 04/02 EDT
开盘
0.4283
昨收
0.4320
最高
0.4369
最低
0.4100
成交量
28.30万
成交额
--
52周最高
3.450
52周最低
0.3010
市值
2,090.76万
市盈率(TTM)
-0.8605
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测LPCN价格均价为3.500,最高价位5.00,最低价为2.000。

EPS

LPCN 新闻

更多
  • 瑞幸称相关人员已停职并被接任 有员工准备另谋出路
  • 新浪财经综合 · 1小时前
  • “大空头”查诺斯:需对因疫情短暂受益的“病毒股”保持谨慎
  • 新浪美股 · 1小时前
  • Recode:亚马逊禁止商家向公众销售N95和医用外科口罩
  • 新浪美股 · 1小时前
  • 你需要了解:新冠病毒将重铸美国科技版图
  • 新浪财经综合 · 1小时前

所属板块

生物技术和医学研究
+0.64%
制药与医学研究
+0.79%

热门股票

代码
价格
涨跌幅

LPCN 简况

Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company's additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip'ral promicellar drug delivery technology platform. Lip'ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.
展开

微牛提供Lipocine Inc(NASDAQ-LPCN)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的LPCN股票新闻,以帮助您做出投资决策。